Skip to main content

Table 1 Baseline patient characteristics

From: Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study

 

All Patients

Pirfenidone

Nintedanib

P Value1

N = 1455

N = 799

N = 656

Age, mean (SD)

70.9 (9.5)

70.6 (9.4)

71.3 (9.7)

0.222

Age categories, years, n (%)

   

0.581

 40–44

1 (0.1)

1 (0.1)

(0.0)

 

 45–54

68 (4.7)

36 (4.5)

32 (4.9)

 

 55–64

377 (25.9)

212 (26.5)

165 (25.2)

 

 65–74

445 (30.6)

255 (31.9)

190 (29.0)

 

 75–79

269 (18.5)

140 (17.5)

129 (19.7)

 

 ≥ 80

295 (20.3)

155 (19.4)

140 (21.3)

 

Female, n (%)

456 (31.3)

256 (32.0)

200 (30.5)

0.525

Region, n (%)

   

0.010

 Northeast

271 (18.6)

157 (19.6)

114 (17.4)

 

 North Central

457 (31.4)

236 (29.5)

221 (33.7)

 

 South

554 (38.1)

294 (36.8)

260 (39.6)

 

 West

169 (11.6)

111 (13.9)

58 (8.8)

 

 Unknown

4 (0.3)

1 (0.1)

3 (0.5)

 

CCI, mean (SD)

2.1 (2.0)

2.1 (2.0)

2.1 (1.9)

0.512

   excluding COPD, mean (SD)

1.9 (2.0)

1.9 (2.0)

1.9 (1.9)

0.680

Proxies of disease severity, n (%)

 Presence of supplemental oxygen use

868 (59.7)

478 (59.8)

390 (59.5)

0.885

 Diagnosis of dyspnea

1131 (77.7)

621 (77.7)

510 (77.7)

0.992

 Prescription for ≥1 opioid(s)

557 (38.3)

306 (38.3)

251 (38.3)

0.989

Presence of comorbid conditions, n (%)

 Any cardiovascular disease

640 (44.0)

354 (44.3)

286 (43.6)

0.787

  Stroke

37 (2.5)

23 (2.9)

14 (2.1)

0.369

 COPD

692 (47.6)

359 (44.9)

333 (50.8)

0.027

  Emphysema

189 (13.0)

99 (12.4)

90 (13.7)

0.453

  Bronchitis

101 (6.9)

51 (6.4)

50 (7.6)

0.355

  Chronic bronchitis

156 (10.7)

73 (9.1)

83 (12.7)

0.031

  Chronic airway obstruction

562 (38.6)

289 (36.2)

273 (41.6)

0.034

 Cancer

269 (18.5)

154 (19.3)

115 (17.5)

0.394

  Lung cancer

31 (2.1)

21 (2.6)

10 (1.5)

0.147

 Recent pnemonia2

149 (10.2)

77 (9.6)

72 (11.0)

0.402

All-cause total costs, mean (SD)

$31,933 ($54,125)

$31,849 ($44,706)

$32,035 ($63,781)

0.948

Visit to ILD center of excellence3, n (%)

110 (7.6)

57 (7.1)

53 (8.1)

0.497

  1. CCI Charlson Comorbidity Index, COPD chronic obstructive pulmonary disease, SD standard deviation
  2. 1Pirfenidone vs. nintedanib
  3. 2Pneumonia diagnosis in the 3 months immediately preceding the index date
  4. 3 Patient was treated at an Interstitial Lung Disease (ILD) Center of Excellence as identified by zip code of facility. Centers of excellence were defined as medical centers with specific expertise in the treatment of pulmonary fibrosis, as recognized by the Pulmonary Fibrosis Foundation
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us